RSA launches RSA Talent Equity Reports
The first report provides insight and opinion on the type of talent which makes European biotech a vibrant industry, and profiles ten CEOs and the top 25 Venture Capital funded biotech companies from the last ten years.
The RSA Talent Equity&trade report offers an understanding into what makes transformational people effective across the entire range of the Life Sciences sectors. It also identifies the key players and the skills which they apply to achieve success.
Using data from EvaluatePharma and other industry sources, RSA analysed 551 venture-backed biotech companies and their strategic transactions, which included: 3,105 licensing deals, 178 IPOs and 629 M&A transactions. This data identified the most successful European biotech companies and the executive talent behind them. RSA also used proprietary performance measurement criteria and their own extensive industry insight to select the talent pool according to the company’s performance against each of the indicators. Finally, using their talent and sector expertise, RSA have pinpointed key traits of the CEOs who drove success at these biotech companies.
Future RSA Talent Equity&trade reports will provide insight into a range of vibrant industry sectors and represents only the surface of RSA’s deep understanding into the Talent Equity that drives the Life Sciences industry.
Chris Molloy, CEO of RSA commented, “We all work in a learning environment and at every level, from Bench to Boardroom, we all have something to learn. As the industry evolves, so does our knowledge of the type of Talent needed to drive success and value.”
“For too long, executive search firms have used information on talent as their key proprietary asset. We provide deep analysis and due diligence on that talent and believe in providing clients with insight,” concludes Chris.